newsfilter
← Latest News
PR Newswire·

Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain

MDT
  • Medtronic completed its acquisition of SPR Therapeutics for $650 million in upfront cash on July 16, 2026.
  • The deal adds the FDA-cleared SPRINT® PNS System to Medtronic's pain therapy portfolio.
  • SPRINT® is a short-term, minimally invasive peripheral nerve stimulation therapy that does not require a permanent implant.
  • Clinical data from 13 studies shows 60% of patients achieved ≥50% pain reduction after the 60-day treatment, with responders seeing an average 76% reduction.
  • The acquisition is expected to be minimally dilutive to Medtronic's adjusted EPS in fiscal year 2027 & neutral to accretive thereafter.
  • The SPRINT® system aims to expand non-opioid & non-surgical treatment options for chronic & acute pain management.